We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Last summer, Ironwood pink-slipped 40 staffers as it prepared to split itself into two companies. But it turns out those layoffs were only the beginning.
Chairman Philip Hampton, who joined GlaxoSmithKline after its Novartis asset swap upped the ante in consumer health, is now stepping down as the British drugmaker prepares to split up the business.
Chairman Philip Hampton, who joined GlaxoSmithKline after its Novartis asset swap upped the ante in consumer health, is now stepping down as the British drugmaker prepares to split up the business.